earnings
LE
NASDAQ · LENZ
LENZ Therapeutics, Inc.
Healthcare · Biotechnology
$5.96
Up+$0.13 (+2.23%)
Updated Sep 7, 2026, 2:42 AM
SID Score
4.1/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 684.09M
- P/E ratio
- -13.13
- Dividend yield
- 0.00%
- 52-week range
- $4.54 – $50.40
- Volume
- 488.96K
- Avg. volume
- 997.98K
Price performance
LENZ price history
1M range · 20 trading sessions · Daily adjusted prices
LENZ closed at $5.96 after 20 trading sessions, up 11.19% for the selected period.
- Last close
- $5.96
- Period change
- +11.19%
- Period low
- $4.59
- Period high
- $5.96
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 4, 2026 | $5.75 | $5.98 | $5.615 | $5.96 | 488.96K |
| Sep 3, 2026 | $5.90 | $5.97 | $5.65 | $5.83 | 835.14K |
| Sep 2, 2026 | $5.21 | $5.81 | $5.21 | $5.80 | 993.29K |
| Sep 1, 2026 | $5.17 | $5.305 | $5.00 | $5.23 | 605.58K |
| Aug 31, 2026 | $5.06 | $5.275 | $5.008 | $5.21 | 713.74K |
| Aug 28, 2026 | $4.80 | $5.13 | $4.69 | $5.11 | 680.21K |
| Aug 27, 2026 | $4.78 | $4.8328 | $4.7182 | $4.81 | 439.22K |
| Aug 26, 2026 | $4.67 | $4.84 | $4.58 | $4.78 | 546.04K |
| Aug 25, 2026 | $4.58 | $4.81 | $4.58 | $4.67 | 542.23K |
| Aug 24, 2026 | $4.65 | $4.70 | $4.5467 | $4.59 | 497.91K |
| Aug 21, 2026 | $4.71 | $4.81 | $4.67 | $4.68 | 475.32K |
| Aug 20, 2026 | $4.88 | $4.90 | $4.575 | $4.66 | 567.53K |
| Aug 19, 2026 | $4.82 | $5.036 | $4.81 | $4.92 | 583.51K |
| Aug 18, 2026 | $4.77 | $4.89 | $4.74 | $4.77 | 534.41K |
| Aug 17, 2026 | $4.71 | $4.82 | $4.60 | $4.79 | 804.84K |
| Aug 14, 2026 | $4.63 | $4.87 | $4.63 | $4.73 | 702.71K |
| Aug 13, 2026 | $5.02 | $5.25 | $4.535 | $4.60 | 1.43M |
| Aug 12, 2026 | $5.93 | $6.74 | $5.01 | $5.04 | 2.14M |
| Aug 11, 2026 | $5.41 | $5.48 | $5.05 | $5.21 | 530.04K |
| Aug 10, 2026 | $5.38 | $5.4778 | $5.29 | $5.36 | 441.85K |
Latest LENZ news
The latest Smart Investors Daily articles mentioning LENZ.
Stock researchResearch & News · SEC Filings
Loading stock research…